Electra Therapeutics, Inc. SEC filings ETRA
Electra Therapeutics, Inc. has 34 filings in SEC EDGAR's recent list, going back to Oct 30, 2025. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (bylaw or fiscal year change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 29, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 28, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 28, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Sep 25, 2026 | — |
| 4 | Insider transaction | Sep 23, 2026 | Sep 21, 2026 |
| 4 | Insider transaction | Sep 23, 2026 | Sep 21, 2026 |
| 3 | Initial insider ownership | Sep 21, 2026 | Sep 21, 2026 |
| 4 | Insider transaction | Sep 21, 2026 | Sep 21, 2026 |
| 4 | Insider transaction | Sep 21, 2026 | Sep 21, 2026 |
| 4 | Insider transaction | Sep 21, 2026 | Sep 21, 2026 |
| 4 | Insider transaction | Sep 21, 2026 | Sep 21, 2026 |
| S-8 | Employee stock plan registration | Sep 21, 2026 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Sep 21, 2026 | Sep 21, 2026 |
| 424B4 | Prospectus | Sep 18, 2026 | — |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| 3 | Initial insider ownership | Sep 18, 2026 | Sep 18, 2026 |
| CERT | Filing | Sep 18, 2026 | — |
| 8-A12B | Filing | Sep 18, 2026 | — |
| EFFECT | Filing | Sep 17, 2026 | — |
| S-1MEF | Filing | Sep 17, 2026 | — |
| S-1/A | Amended registration statement | Sep 14, 2026 | — |
| S-1 | Registration statement | Aug 28, 2026 | — |
| DRS/A | Filing | Aug 10, 2026 | — |
| DRS | Filing | Jun 26, 2026 | — |
| D | Filing | Oct 30, 2025 | — |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ETRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2088082
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.